Smith+Nephew partners with SI-BONE for pelvic fracture fixation solutions

The distribution agreement expands Smith+Nephew's trauma portfolio and strengthens its position in high-impact procedures.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Smith+Nephew, the global medical technology company, has signed a distribution agreement with SI-BONE to offer the iFuse TORQ portfolio of solutions for percutaneous pelvic fracture fixation and sacroiliac joint fusion. This collaboration combines SI-BONE's industry leadership with Smith+Nephew's commercial platform to expand access to differentiated trauma solutions and drive sustainable growth.

Why it matters

The partnership allows Smith+Nephew to strengthen its position in the high-frequency, high-impact trauma market by offering innovative solutions like the iFuse TORQ portfolio, which has received FDA Breakthrough Device Designation for its potential to provide more effective treatment of pelvic fractures compared to traditional methods.

The details

The iFuse TORQ portfolio includes the iFuse TORQ TNT and iFuse TORQ implants, designed specifically to address the anatomical and bone density needs of the sacrum and ilium. The iFuse TORQ TNT implant is eligible for a Medicare New Technology Add-on Payment, which may provide up to $4,136 in additional reimbursement per procedure for hospitals.

  • The distribution agreement was signed on February 23, 2026.

The players

Smith+Nephew

A global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue.

SI-BONE

A global leader in developing procedural solutions to address clinical challenges associated with compromised bone, including the iFuse TORQ portfolio for pelvic fracture fixation and sacroiliac joint fusion.

Scott Gunn

Vice President of Trauma, Extremities and Shoulder at Smith+Nephew.

Got photos? Submit your photos here. ›

What they’re saying

“We're incredibly excited to partner with SI-BONE. This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE's industry leadership with Smith+Nephew's established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth.”

— Scott Gunn, Vice President Trauma, Extremities and Shoulder (Smith+Nephew)

What’s next

The partnership is expected to expand Smith+Nephew's ability to serve surgeons and patients in the high-need area of pelvic fracture fixation and sacroiliac joint fusion.

The takeaway

This distribution agreement allows Smith+Nephew to bolster its trauma portfolio with innovative solutions like the iFuse TORQ, which has the potential to provide more effective treatment of pelvic fractures compared to traditional methods and may receive additional Medicare reimbursement, benefiting both hospitals and patients.